SRF617

Poster: First-in-human phase 1 trial of SRF617, a potent inhibitor of CD39 activity, as monotherapy or in combination, in patients with advanced solid tumors

European Society for Medical Oncology Immuno-Oncology Congress, December 2021

Poster: The fully human antibody SRF617 is a potent inhibitor of ecto-enzyme CD39 in vivo

Society for Immunotherapy of Cancer, November 2021

Poster: CD39 Inhibition Shapes the Transcriptional Landscape of Myeloid Cells and Induces Proinflammatory States in the CT26 Syngeneic Tumor Model

American Association for Cancer Research Annual Meeting, April 2021

Poster: SRF617, a potent enzymatic inhibitor of CD39, demonstrates single-agent activity and cooperates with various cancer therapies in both solid tumor and hematologic malignancies